Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:06:30.003Z.
Calculation as of: 2026-10-06T18:06:30.003Z.
Quote observation: 2026-10-06T17:58:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3fd66fa07f89ff8c2236b8eda0ba832ed38a6b1a46891be7cbf8760d0061f77
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
XORTX Therapeutics Inc.
Market Cap
$481786.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$381940.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$377001.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$843188.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $481786.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $523743.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $552784.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $377001.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $669377.00 | 0.01 | 0.16 | 40.30 | 40.30 |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $801835.00 | N/A | 0.30 | 0.38 | 0.32 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $843188.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
